Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T-cell-prolymphocytic Leukemia: early-phase trial registry
5 of 8 indexed T-cell-prolymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count
T-cell-prolymphocytic Leukemia: 8 US clinical trials tracked, 5 recruiting.
T-cell-prolymphocytic Leukemia is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition t-cell-prolymphocytic-leukemia
OPEN 5 | RECR 63% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
T-cell-prolymphocytic Leukemia lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for T-cell-prolymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
T-cell-prolymphocytic Leukemia is recruiting above its size-band peers.
5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates T-cell-prolymphocytic Leukemia research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most T-cell-prolymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
T-cell-prolymphocytic Leukemia research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
A Registry for People With T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05978141
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical
NCT04771572
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05010005
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT07356245
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
NCT06810778
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05823571
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT05377827
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
NCT04312841
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on T-cell-prolymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on T-cell-prolymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this T-cell-prolymphocytic Leukemia page
8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 T-cell-prolymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most T-cell-prolymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This T-cell-prolymphocytic Leukemia condition card totals 8 registered trials; most-linked intervention Duvelisib; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.